Research into the treatment of non-Hodgkin lymphoma (NHL) has made great progress within the last decade, with clinical trials such as the TRANSCEND-OUTREACH-007 and ZUMA-12 studies successfully advancing into later phases. Although there are currently various approaches to NHL treatment, primarily employing chemotherapy, steroid medication and allogeneic stem cell transplantation, such approaches are not tolerated by all patients and may not achieve complete remissions, creating an opening for immunotherapies to address these challenges. Given the recent FDA approvals of chimeric antigen receptor T-cell (CAR-T) therapies such as idecabtagene vicleucel and lisocabtagene maraleucel, much attention has now turned to the potential of these novel cellular therapies for more effective treatment of NHL.
In this podcast, Jeremy Abramson of the Massachusetts General Hospital Cancer Center, Boston, MA, Sattva Neelapu of the University of Texas MD Anderson Cancer Center, Houston, TX, Stephen Schuster of the Perelman School of Medicine, Philadelphia, PA, Barbara Savoldo of the University of North Carolina at Chapel Hill, Chapel Hill, NC, Max Mamonkin of the Baylor College of Medicine, Houston, TX, and Susan Prockop of the Memorial Sloan Kettering Cancer Center, New York, NY, discuss the latest clinical updates on T-cell therapies for NHL, highlighting therapies such as lisocabtagene maraleucel and axicabtagene ciloleucel.
The AML sessions: venetoclax-based regimens
The AML Sessions: IDH inhibitors
The AML sessions: advances in immuno-oncology from SOHO 2020
Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
SOHO 2020: Next questions in hematological malignancies
CLL therapy: the latest trial updates and innovative novel therapies for the future
The MPN Sessions: pathobiology, therapeutic strategies & clinical trials
Latest AML therapies: novel preparations and first in class agents
Advances in the lymphoma space: targeted therapies, PET-guided omission of RT and CAR T-cells
The Myeloma Sessions: Evolving management of myeloma & COVID-19
CLL: MRD and first-in-class agents
MPNs highlights at EHA 2020: clinical trials, novel therapies & pitfalls
The CLL Sessions: frontline therapy, BTK inhibitors, MRD negativity & novel therapies
The HemOnc & COVID-19 Sessions: treating hematological malignancies, reducing nosocomial COVID-19 infections, clinical trial participation and resourc...
The AML Sessions: emerging immunotherapies, venetoclax-based regimens and targeted therapies in AML
Key updates in ALL at EHA 2020
The Myeloma Sessions: smoldering myeloma, MRD evaluation, R/R disease & transplant-eligible patients
Systemic mastocytosis: current landscape, novel agents and COVID-19
MRD assessment in AML: incorporation into clinical practice
Myeloma management in the COVID-19 era
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive